Inflammatory markers S100A8/A9 and metabolic alteration for evaluating signs of early phase toxicity of anticancer agent treatment

Food Chem Toxicol. 2022 Nov:169:113421. doi: 10.1016/j.fct.2022.113421. Epub 2022 Sep 10.

Abstract

Anticancer agents can cause various side effects, including tissue damages/inflammatory reactions. Drug-responsive biomarkers are essential for evaluating drug toxicity in disease processes. S100 calcium-binding proteins A8/A9 (S100A8/A9) are highly expressed in neutrophils and monocytes/macrophages accumulated at inflammatory sites and are known to be related to tissue damage/inflammation; however, their response to drug toxicity has not been reported. Herein, we investigated the effects of anticancer agents (doxorubicin, cisplatin, and docetaxel) on S100A8/A9 gene expression profiles in four representative tissues (heart, kidney, liver, and lung) in normal C57BL/6J mice. Both S100A8/A9 expression was transiently or time-dependently elevated in four tissues within 48 h after dosing of the three anticancer agents under toxicity-inducing conditions. S100A8/A9 patterns differed among agents and tissues. This result suggests that S100A8/A9 is useful for evaluating anticancer agent-induced tissue damage. Metabolomic analysis revealed that some metabolites showed temporal patterns similar to that of S100A8/A9 expression. The amounts of fumarate (doxorubicin-treated heart), tyrosine (cisplatin-treated kidney), acetylcarnosine (doxorubicin-treated liver), and 2-phosphoglycerate (docetaxel-treated lung) showed similar patterns to that of S100A8/A9 expression. Although these metabolites showed different behaviors between tissues and serum, they may be useful marker candidates for evaluating anticancer agent-induced tissue damage at an earlier stage after dosing.

Keywords: Anticancer agent; Biomarker; Drug toxicity; Inflammation; Metabolome analysis.

MeSH terms

  • Animals
  • Antineoplastic Agents* / administration & dosage
  • Antineoplastic Agents* / toxicity
  • Biomarkers, Pharmacological* / metabolism
  • Calgranulin A* / genetics
  • Calgranulin A* / metabolism
  • Calgranulin B* / genetics
  • Calgranulin B* / metabolism
  • Cisplatin / administration & dosage
  • Cisplatin / toxicity
  • Docetaxel / administration & dosage
  • Docetaxel / toxicity
  • Doxorubicin / administration & dosage
  • Doxorubicin / toxicity
  • Fumarates / analysis
  • Inflammation* / chemically induced
  • Inflammation* / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Tyrosine / analysis

Substances

  • Antineoplastic Agents
  • Biomarkers, Pharmacological
  • Calgranulin A
  • Calgranulin B
  • Cisplatin
  • Docetaxel
  • Doxorubicin
  • Fumarates
  • S100a8 protein, mouse
  • S100A9 protein, mouse
  • Tyrosine